Clinical Updates & Treatment Advances in Metastatic Cervical Cancer from SGO
SGO 2022 Final OS Results From SOLO3: Phase III Trial Assessing Olaparib Monotherapy vs. Non-Platinum Chemo in Heavily Pretreated Patients With Germline BRCA1 and/or BRCA2m Platinum-Sensitive Relapsed Ovarian Cancer
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
Richard Penson
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
Richard Penson
Login to view comments.
Click here to Login
